

Serotonin 2B receptor potentiates erythropoietin-induced mobilization of endothelial progenitor cells: contribution to hypoxic pulmonary arterial hypertension?

Estelle Ayme-Dietrich, Jerome Becker, Ghina Bou About, Luc Maroteaux, Lahcen El Fertak, M Denu, P Reilly, E Peter-Thiebaut, Yann Hérault, H Jacobs, et al.

▶ To cite this version:

Estelle Ayme-Dietrich, Jerome Becker, Ghina Bou About, Luc Maroteaux, Lahcen El Fertak, et al.. Serotonin 2B receptor potentiates erythropoietin-induced mobilization of endothelial progenitor cells: contribution to hypoxic pulmonary arterial hypertension?. Annual Meeting of French Society of Pharmacology and Therapeutics, and INSERM Clinical Research Centers (CIC), Jun 2018, Toulouse, France. hal-03960373

HAL Id: hal-03960373 https://hal.science/hal-03960373

Submitted on 27 Jan 2023 $\,$

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés. PM1 - 049

Serotonin 2B receptor potentiates erythropoietin-induced mobilization of endothelial progenitor cells: contribution to hypoxic pulmonary arterial hypertension?

E Ayme-Dietrich^a, J Becker^b, G Bou About^b, E Peter-Thiebaut^b, L El Fertak^b, M Denu^b, H Jacobs^b, P Reilly^b, Y Herault^b, L Maroteaux^c, L Monassier^a

^aLaboratoire de Pharmacologie et Toxicologie NeuroCardiovasculaire, EA7296, Federation de Medecine Translationnelle, Faculte de Medecine, Hopital et Universite de Strasbourg – Strasbourg (France);

^bInstitut Clinique de la Souris-ICS-MCI, PHENOMIN, CNRS UMR7104, INSERM U964, Universite de Strasbourg – Illkirch (France);

^cINSERM UMR S-839, Institut du Fer a Moulin – Paris (France)

Introduction: Pulmonary arterial hypertension (PAH) is characterized by increased pulmonary vascular resistance leading to right ventricular failure. Chronic hypoxia increases plasma levels of erythropoietin (Epo), a hormone that has been shown to promote mobilization of endothelial progenitor cells (EPCs). During hypoxia, the 5-HT2B receptor-mediated mobilization of EPCs from the bone-marrow contributes to PAH [1]. In the present work, we tested the hypothesis that (i) Epo recapitulates features of hypoxic PAH and (ii) serotonin and Epo interact together in the bone marrow to mobilize EPCs leading to PAH.

Material and methods: (i) In wild-type (Htr2B+/+) mice, we compared the effects of recombinant human Epo (3 injections of 3500 UI/kg per week, 2 weeks) and hypoxia (2 weeks normobaric 10% FiO2), on hemodynamics, pulmonary vascular remodeling, hematological analysis and mobilization of EPCs. ii) In Htr2B+/+ and knockout (Htr2B-/-) mice, we compared the blood mobilization of EPCs by FACS, after the stimulation of 5-HT2B receptors by nordexfenfluramine (1 mg/kg/day, 14 days) and/or Epo stimulation. Erythropoiesis (blood cells count) and pulmonary vascular remodeling were also evaluated.

Results: In normoxia, Epo recapitulates all hemodynamic and structural alterations of hypoxiainduced PAH (increase of right ventricular pressure, pulmonary vascular remodeling, increase of red blood cells count and hematocrit). Then, nordexfenfluramine and Epo increase EPCs count 5–10 times in Htr2B+/+ mice blood. The mobilization of EPCs is potentiated by the 5-HT2B and Epo receptors simultaneous stimulation in Htr2B+/+ mice, whereas it is prevented in Htr2B-/- mice blood. Concerning erythropoiesis, Epo treatment induces similar increase of red blood cells count, hematocrit and hemoglobin levels in Htr2B+/+ and Htr2B-/- mice. The analysis of pulmonary vascular remodeling is currently under investigation.

Discussion/Conclusion: These data further emphasize the contribution of EPCs mobilization in the mechanisms of PAH, and confirm that serotonin and EPO both trigger EPCs mobilization. A pharmacological synergism between EPO and 5-HT2B receptors is suggested and will be investigated. Blockade of serotonin 5- HT2B receptors could be a therapeutic target to prevent Epo-induced PAH, without affecting the erythropoiesis response.

Reference

[1] Launay J.M. et al. Serotonin 5-HT2B receptors are required for bone-marrow contribution to pulmonary arterial hypertension. Blood (2012) 119 1772–1780.